Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 3

Status

Terminated 2Completed 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 4Lymphoid 3Dermatologic 3Thoracic 2Breast 2Sarcoma 1Other neoplasm 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1

Conditions

Melanoma 3

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × tanespimycin × Dermatologic × Clear all
NCT00104897 2013-06-26

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
25 enrolled
Dermatologic

Melanoma

NCT00087386 2013-04-10

Tanespimycin in Treating Patients With Stage III-IV Melanoma

National Cancer Institute (NCI)

Phase 2 Terminated
50 enrolled
Dermatologic

Melanoma

NCT00627419 2012-12-10

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

Infinity Pharmaceuticals, Inc.

Phase 2 Terminated
1 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡